Showing 1489 results
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR FDA concluded that OAV-101 intrathecal (IT) clinical program may proceed based on data from nonclinical toxicology study New Phase 3 STEER study will…
-
Press release /Data analysis shows that preventing the symptoms of CSU (achieving complete control) improves overall health-related quality of life (HRQoL); including sleep and work productivity, among other…
-
Press release /New clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm Cytokine storm is a type of severe immune overreaction that can result from coronavirus…
-
Press release /C3 glomerulopathy (C3G) is a rare renal disease, affecting young patients with a poor prognosis and significant unmet need.1–3 Iptacopan (LNP023) is a potential first-in-class, oral,…
-
Press release /In a post-hoc analysis of HAWK and HARRIER, fewer Beovu (brolucizumab) patients had early persistent fluid (12.5% vs. 20.4% of aflibercept patients), defined as the presence of intra-retinal fluid…
-
Ad hoc release /Ad hoc announcement pursuant to Art. 53 LR With two maintenance doses a year, Leqvio is the first and only FDA-approved small interfering RNA (siRNA) therapy for LDL-C (bad cholesterol…
-
Press release /Conatus today announced top-line results from the ENCORE-LF trial, which did not meet its primary endpoint Novartis remains fully committed to pursuing the development of multiple compounds in…
-
Press release /The AVXS-101, now known as ZOLGENSMA® (onasemnogene abeparvovec-xxxx)[1], filing is supported by data from the START trial which demonstrated a dramatic increase in survival and transformative…
-
Press release /Once-daily QMF149 met primary endpoint of lung function improvement and key secondary endpoint of asthma control improvement versus mometasone furoate1 QMF149 showed improvement in peak…
-
Press release /Results from year two of the pivotal Phase III KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one1,2 In key fluid-related…